Active surveillance ‘safe and effective’ for low-risk prostate cancer
Active surveillance is an effective management strategy for men with favourable-risk prostate cancer, with an estimated rate of metastasis of 1.4% at 10 years after…
Tag: prostate cancer
MRI plus blood test results may cut unnecessary biopsies for prostate cancer
Prostate biopsies may not be necessary for patients with equivocal or negative MRI results and low PSA density, according to US findings. Authors conducted a…
Small boost in fitness enough to cut prostate cancer risk: study
Even small increases in cardiorespiratory fitness can significantly reduce the risk of developing prostate cancer, researchers report. An annual increase in aerobic fitness of 3%…
Alpha therapy a ‘viable option’ for metastatic castration-resistant prostate cancer
Targeted alpha therapy is safe and effective for treating metastatic castration-resistant prostate cancer when other anticancer agents have failed, show results from the largest trial…
We need to embrace these tests to stop overtreating prostate cancer
Urology has evolved dramatically over the course of my 30-year career, with exciting advances in prostate cancer treatment. Most healthcare professionals will be familiar with…
Prostate cancer treatment ‘does not alter’ 15-year survival: major study
Men with localised prostate cancer have high long-term survival rates regardless of whether they choose a ‘watch and wait’ approach or radical treatment, a landmark…
Doctors could predict aggressive prostate cancer earlier with Aussie research
Epigenetic biomarkers to predict more aggressive forms of prostate cancer have been identified by researchers at the Garvan Institute of Medical Research. Combined with traditional…
Prostate cancer risk after TURP ‘low’ for men with PSA levels <10ng/mL
A large database study identifies the cut-point warranting increased surveillance.
Focused ultrasound controls prostate cancer with fewer side effects: study
The tissue-preserving approach could eliminate the need for radical whole-gland treatment, researchers say.
Androgen deprivation therapy ‘ups all-cause mortality risk’
Men receiving the therapy for prostate cancer are also more likely to experience adverse CV outcomes, researchers say.
